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Effect of Two Different Neuroprotection
Systems on Microembolization During
Carotid Artery Stenting
After reading the study titled “Effect to Two Different Neuropro-
tection Systems on Microembolization During Carotid Artery
Stenting” by Schmidt et al. (1) in the Journal and after having an
extensive experience with a system that holds several similarities
with the MO.MA device (Invatec s.r.l., Roncadelle, Italy), I can
make the following comments.
The investigators stated that 71% of their patients had microem-
bolic signals (MESs) after balloon dilation of the stent; MESs during
stent placement and balloon dilation were more than six times higher
than during wire passage. This latter observation suggests that
antegrade flow was still present using the MO.MA device.
The utilization of balloon occlusion of the common carotid
artery (CCA) and external carotid artery (ECA) and the descrip-
tion of continuous MESs during carotid artery stenting (CAS)
using a filter device was reported earlier by us (2). The researchers
did not reference this original study.
Using occlusion of the CCA and ECA, we experienced, as did
Schmidt et al. (1), that MESs were still present; we attributed
them to antegrade flow through branches not occluded by the
balloon. The other potential explanation is a Venturi effect of the
circle of Willis suctioning from the column of stagnant flow in the
internal carotid artery after balloon occlusion.
Finally, owing to the above-mentioned findings, we added flow
reversed to the occlusion of the CCA and ECA.
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REPLY
Dr. Parodi mentions his experience with a similar protection
device, the PAES (Parodi antiembolism system) (1). Because of
the requirement of brevity of our study (2), the comparative
technical discussion of both systems (MO.MA vs. PAES) was not
possible. An advantage of the PAES over the MO.MA system
could be the potential continuous retrograde flow through the
target lesion during the intervention. Establishment of a continu-
ous retrograde flow in the internal carotid artery using this concept
has been demonstrated in an animal model (3). However, there are
no scientific data demonstrating and quantifying that, during the
critical phases of stent placement, delivery and postdilation of the
PAES permits an effective retrograde flow in humans. Dr. Parodi
mentioned in his study (1) the use of this protection device in nine
patients. Transcranial Doppler monitoring revealed no microem-
bolic signals (MESs) during clamping of the common carotid
artery in these patients. In our study, using the MO.MA system
there was also a considerable number of subjects (48% of 21
patients) showing no MESs during stent deployment and during
balloon dilation (29% of 21 patients). It is regrettable that a
controlled multicenter registry, showing the safety and feasibility
of the PAES, as it has been conducted recently using the MO.MA
system (4), is not yet available. A randomized comparison between
the PAES and MO.MA device using transcranial Doppler with
detection of MESs would be of interest.
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